Skip to main content
logo
Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
45.29
+0.92 (2.09%)
Sep 16, 2026, 2:48 PM EDT - Market open

Rigel Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
276.79294.28179.28116.88115.74138.74
Revenue Growth
3.31%64.15%53.38%0.98%-16.57%27.73%
Gross Profit
209.27241.37137.2585.2553.7272.42
Operating Income
87.05125.4724.19-20.49-58.73-19.48
Net Income
321.91367.0217.49-25.09-58.57-17.91
Earnings Per Share
16.4519.480.99-1.44-3.44-1.05
EPS Growth
202.71%1867.68%----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
95.33154.9677.3256.9358.21124.97
Total Debt
39.9553.399.95104.1787.7591.27
Net Cash (Debt)
55.38101.65-22.63-47.23-29.5533.7
Net Cash Growth
16.99%----84.77%
Net Cash Per Share
2.835.40-1.28-2.71-1.731.98

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
79.3975.6631.47-5.74-73.765.88
Capital Expenditures
---0.04--0.45-0.63
Free Cash Flow
79.3975.6631.44-5.74-74.215.25
Free Cash Flow Growth
20.67%140.67%----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
75.61%82.02%76.56%72.94%46.41%52.20%
Operating Margin
31.45%42.63%13.49%-17.53%-50.74%-14.04%
Pretax Margin
30.92%41.40%10.24%-21.47%-50.61%-12.48%
Profit Margin
116.30%124.72%9.75%-21.47%-50.61%-12.91%
FCF Margin
28.68%25.71%17.53%-4.91%-64.11%3.79%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
2.702.1216.95---
Forward PE
13.8310.4917.39---
P/FCF Ratio
10.6310.289.43--86.30
PS Ratio
3.052.641.652.162.243.27